Péter Reményi, László Gopcsa, Imelda Marton, Marienn Réti, Gábor Mikala, Mónika Pető, Anikó Barta, Arpád Bátai, Zita Farkas, Zita Borbényi, Zoltán Csukly, Imre Bodó, János Fábián, Agnes Király, Lilla Lengyel, Klára Piukovics, Eva Torbágyi, Tamás Masszi
INTRODUCTION: Biosimilar versions of filgrastim [recombinant human granulocyte colony-stimulating factor (rhG-CSF)] are now widely available. To date, biosimilar rhG-CSF has demonstrated a comparable quality, safety and efficacy profile to the originator product (filgrastim [Neupogen(®)], Amgen Inc., CA, USA) in the prevention and management of neutropenia. Biosimilar rhG-CSFs have also been used to induce peripheral blood stem cell (PBSC) mobilization in patients undergoing autologous stem cell transplantation (AHSCT)...
April 2014: Advances in Therapy